|
|
|
|
|
News, Reviews, and Articles on Intravascular Hemolysis
Soliris(R) Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis Jun 15, 2008
Key findings included the following: * While intravascular hemolysis reduction (decreased LDH) and anemia improvement (increased hemoglobin) were both significantly associated with fatigue improvement (odds ratio 1. 11, P. (PR Newswire)
Eculizumab is Well Tolerated and Demonstrates Significant Improvement During 52 Weeks of Treatment in Open-Label Phase III SHEPHERD Study in PNH Patients Dec 10, 2006
Dec. 9 /PRNewswire-FirstCall/ -- Eculizumab, a novel monoclonal antibody investigational drug developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ), appeared to be safe and well tolerated and provided clinically and statistically significant improvements in intravascular hemolysis, anemia, fatigue and quality of life in patients with paroxysmal nocturnal hemoglobinuria (PNH) during the 52 weeks of treatment in the Phase III SHEPHERD open-label clinical trial ... The pre-specified primary... (PR Newswire)
Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Sep 21, 2006
Biochemical indicators of intravascular hemolysis and the patients' quality of life were also assessed ... Eculizumab reduced intravascular hemolysis, as shown by the 85. (New England Journal of Medicine)
[ Terms Of Use | Privacy | About ]
©1998-2006 SurfWax, Inc.
All rights reserved. Patents pending.
|
|
|
Copyright SurfWax, Inc. 2006
|
|